Trial Profile

Multicenter explorative study of the beneficial effect of Luseogliflozin on cardiovascular function in Japanese T2DM patients (LUSCAR Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luseogliflozin (Primary) ; Antihypercalcaemics
Indications Cardiovascular disorders; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms LUSCAR Study

Most Recent Events

24 Aug 2020 New trial record
18 Aug 2020 Primary endpoint (Variations of CAVI from the beginning of treatment to week 4 and week 12) has not been met, according to
18 Aug 2020 Results published in the Journal of Clinical Hypertension (Greenwich)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com